A novel approach to treating Endometriosis-Related Repeated IVF failures- insights from single case report.

Reprod Biol EndocrinolSep 24, 2026 (epub)
Case ReportObstetrics & GynecologyOpen access

Raoul Orvieto

✦ AI-curated · Sources linked

Case in brief

A young nulligravida with peritoneal endometriosis experienced recurrent implantation failure and poor embryo quality during multiple IVF attempts. After a pretreatment with Dienogest, she underwent a combined protocol of Stop GnRH-agonist/GnRH-antagonist for ovarian stimulation, followed by a natural cycle frozen-thawed embryo transfer. This approach resulted in the production of high-quality embryos and a successful singleton pregnancy.

Diagnostic / clinical pearl

Clinicians should consider a combined hormonal protocol and natural cycle embryo transfer in patients with endometriosis-related repeated IVF failures to improve embryo quality and pregnancy outcomes.

Source

PubMed · PMID 42786469Free full text on PubMed Central

Published in Reprod Biol Endocrinol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.